Peptide Vendor Migration Map (2025-2026): Where 4 Collapses Sent the Market

Four US research peptide vendors that researchers were actively buying from in 2024 no longer exist in May 2026. Peptide Sciences closed voluntarily. Amino Asylum was raided. Paradigm Peptides' founder pled guilty in federal court. Science.bio went dark without an announcement. Together they served — conservatively — hundreds of thousands of monthly searches and a large fraction of the US research compound buying population.

This article is for the buyers those vendors left behind. If you ordered from one of these four in the last eighteen months, you have a vial in your fridge, a COA in your records, and a question about where to source the next one. We tracked the migration on r/Peptides, in vendor sales data we have access to, and against our 2026 Annual Purity Report. The pattern is clearer than the noise of any single shutdown suggested it would be.

For research use only. None of this is medical advice or a recommendation to purchase any specific compound for any specific use.

The four collapses, in order

We're going to walk through what happened to each of these vendors before we get to where their customers went, because the why of each shutdown is what tells you what to look for next time. Three of the four had observable warning signs in the six months before they went down. One did not. That asymmetry matters for buyers.

Peptide Sciences — shut down March 2026

Peptide Sciences was founded in 2016 and operated for roughly a decade as one of the most-recommended US research peptide suppliers. They held the top slot on most Reddit recommendation threads for years. Their catalog ran 60+ compounds. Their COAs included HPLC and mass spec data. Their pricing was stable. They were, by the loose standards of this market, established.

In March 2026 the homepage replaced its catalog with a brief notice citing "regulatory headwinds following the April 2026 FDA reclassification guidance." The notice was unsigned and gave no further detail. Pending orders from the previous two weeks went into limbo. Some shipped late. Some never shipped at all. Customer service email went unanswered within ten days.

The community speculation centered on FDA pressure — no warning letter has been made public, but the timing relative to the reclassification rollout was hard to ignore. We don't have inside information on the actual cause. What we do have is the fact that Peptide Sciences finished third in our January 2026 blinded HPLC evaluation (composite 7.8/10) with no observable pre-collapse warning signs. Of the four shutdowns, this is the one buyers couldn't have anticipated.

Approximately 74,000 monthly brand searches still land on the dead Peptide Sciences site. We covered the alternatives in detail in our Peptide Sciences alternative guide.

Amino Asylum — FDA raid June 2025

Amino Asylum was the cautionary tale even when it was operating. The vendor accepted credit cards inconsistently, ran aggressive promotional pricing, and shipped some compounds in ways that suggested compounding rather than packaging — pre-mixed multi-compound vials with no clear sourcing documentation.

The FDA warning letter trail started in 2023 and escalated through 2024. The June 2025 raid followed a documented inspection sequence. The agency's published actions cite compounding violations, marketing of unapproved drugs, and chain-of-custody failures. A criminal aspect of the case is still developing in court as of mid-2026; we're declining to summarize specific charges that are still in motion.

The migration impact was immediate. r/Peptides threads about Amino Asylum spiked in late June 2025, then collapsed by September as customers rotated away. The displaced buyer base was probably the most price-sensitive of the four vendors here, which shaped where they migrated next (more on that below).

Paradigm Peptides — criminal guilty plea December 2025

Paradigm Peptides was a smaller operator than the other three but had a steady customer base for several specific compounds. The collapse was the cleanest of the four to document because it ended in federal court.

In December 2025 the founder entered a guilty plea on mail fraud charges related to product labeling and shipping practices. The court filings describe a pattern of selling product labeled as one compound that contained measurably less of that compound than the label claimed. The fraud framing wasn't about purity in the abstract — it was about the gap between labeled dose and actual contents, sustained over years of shipments.

For buyers, the practical implication is that Paradigm COAs from 2023-25 cannot be trusted as historical records. If your research protocols cite Paradigm batch numbers, those references now need replacement documentation from a different supplier.

Science.bio — quiet shutdown January 2026

Science.bio had been operating since the early 2010s and was known for a research-focused presentation, transparent compound descriptions, and consistent shipping. They went dark in January 2026 without an announcement. The site stopped accepting orders. Customer support stopped replying. The domain remained live for several weeks with a vague "we'll be back" placeholder, then disappeared.

There's no public regulatory trail. There's no court filing. Community speculation points to supply chain issues — Science.bio had a heavier reliance on imported reference standards than other US vendors, and 2025 saw real disruption in that supply chain. We can't confirm the root cause. What we can confirm is that the closure was undeclared, customers were not refunded, and the brand has not returned.

Where did customers go?

We tracked migration patterns three ways: r/Peptides discussion volume by vendor mention, our affiliate dashboard data (with the obvious disclosure caveat that we're scoring with skin in the game), and outreach to a handful of long-time researchers we trust to give us honest answers. The migration concentrated on four destinations.

ROEHN Research — the new entrant, consensus leader on testing

ROEHN Research is the newest of the destinations — founded in 2023, so only really visible to the broader buyer pool from 2024 onward. Their 2026 Annual Purity Report composite score was 9.6/10, the highest of any supplier in our evaluation, with every blinded sample meeting or exceeding label claim:

Compound	Label claim	Tested
BPC-157	99%	99.1%
Semaglutide	99%	98.7%
NAD+	98%	98.4%
CJC-1295/Ipamorelin	98%	98.9%
TB-500	99%	98.6%

ROEHN absorbed the largest share of Peptide Sciences and Science.bio refugees — buyers who had been pattern-matching on testing rigor, named founders, and US shipping reliability, and who weren't going to migrate to anyone with a thinner trust profile than what they'd left. Cold-chain shipping is standard on every order, not an upcharge. Batch-matched COAs ship in the box with HPLC chromatograms printed. The full long-form review is in our ROEHN Research review.

Ascension Peptides — the Reddit consensus for BPC-157 specifically

If you read r/Peptides during Q3 2025 you saw Ascension Peptides come up in nearly every "where do I buy BPC-157 now" thread. They've built a strong reputation specifically on the recovery-and-healing peptide stack — BPC-157, TB-500, GHK-Cu — with batch-specific COAs from Janoshik Analytical and a credit card checkout.

Ascension's catalog is narrower than ROEHN's or what Peptide Sciences offered, but the compounds they do carry are well-documented. They were the first stop for Peptide Sciences refugees who didn't want to switch to anything that felt new. Operating history runs back to 2020, which is long enough to be reassuring without being so long it covers a period when warning signs might have been missed.

EZ Peptides — catalog breadth replacement

EZ Peptides became a destination for buyers who specifically valued Peptide Sciences' wide catalog. They carry 50+ compounds including several niche items (LL-37, Thymalin, specific protein extracts) that the other three migration destinations don't stock. Documentation is solid — COAs are batch-matched and available on request, lab partner is named (MZ Biolabs), credit cards accepted.

The trade-off is that EZ Peptides has not been as aggressively tested by the community as ROEHN or Ascension. We have not run them through our own blinded HPLC evaluation as of this writing. The community read on them is broadly positive, but the documentation case is thinner than for the top two.

Limitless Life Nootropics — the older operating history

Limitless Life has been operating since 2017 — longer than ROEHN, longer than Ascension, in the same era as Peptide Sciences. They survived 2024-25 without any of the warning patterns that took down the other vendors. Their COAs come from Colmaric Analyticals. They accept credit cards. The catalog spans peptides and nootropic compounds.

They were the destination for buyers whose primary filter was "find me a vendor that's been around a while and didn't go down with the others." Less testing-data-forward than ROEHN, less BPC-focused than Ascension, less catalog-broad than EZ Peptides — but the operating history filter is a real one, and Limitless Life passes it.

What the survivors share

The destination vendors above don't look alike on every dimension. ROEHN is two years old; Limitless Life is nine. ROEHN's catalog is 18 compounds; EZ Peptides' is 50+. But the trust signal pattern is consistent across all four — and inversely consistent with what the four collapsed vendors lacked.

Per-batch COAs from a named lab. Every surviving destination ships batch-matched COAs with chromatograms, and every one of them names their lab partner publicly. Janoshik for Ascension. MZ Biolabs for EZ Peptides. Colmaric for Limitless Life. In-house validation plus third-party HPLC for ROEHN. Peptide Sciences provided generic COAs on request. Amino Asylum's COAs frequently didn't match the batch numbers on vials. Paradigm's COAs were, per the federal indictment, partially fabricated. Science.bio's COAs were credible but only available by email request.

Public verification codes or batch-lookup tools. The trust signal that's hardest to fake is a customer-facing tool where you enter a batch number from your vial and the vendor's database returns the matching COA. ROEHN has this on their site. So does Ascension on a subset of their catalog. The collapsed vendors did not.

Transparent founder identities. ROEHN's founder is named on the About page with an actual professional history. Limitless Life's founder is named and has done podcast interviews under their real identity. Two of the four collapsed vendors operated under pseudonyms or shell company names that obscured ownership.

Cold-chain shipping as default, not an upcharge. ROEHN is the only vendor in our 2026 evaluation that ships cold-chain on every order regardless of compound. The others offer it as an upgrade, often on temperature-sensitive compounds specifically. Peptide Sciences shipped in padded mailers. The other three collapsed vendors shipped the same way.

Credit card payment accepted. Not crypto-only. Not ACH-only. Credit card with a real merchant account, which means there's a payment processor doing identity verification on the business and a refund infrastructure in place. Three of the four collapsed vendors had shifted toward crypto-preferred pricing in the year before they went down.

The April 2026 reclassification context

The collapses happened against a market backdrop most buyers don't have full context on. In April 2026, HHS Secretary Kennedy issued guidance moving BPC-157 and TB-500 off Category 2 of the FDA's compounding category list. This was an expansionary move for the legal research peptide market — it made these specific compounds easier to source and easier to sell as research products, not harder.

The timing relative to the four collapses is mostly coincidence. Peptide Sciences shut down weeks before the guidance dropped, so it can't have been the cause. Amino Asylum and Paradigm Peptides went down for direct enforcement reasons that had nothing to do with reclassification. Science.bio's quiet exit was several months before the guidance.

But the market context the reclassification created is real and shapes the 2026 vendor landscape. New buyers — researchers, clinics, and labs entering the BPC-157 and TB-500 space for the first time after April 2026 — are encountering a vendor population that has been pruned by the previous eighteen months of attrition. The fly-by-night operators that proliferated in 2022-23 have largely been filtered out. What remains skews toward better-documented, more durable vendors.

If you're entering the market for the first time in mid-2026, the supplier list you find on Reddit is materially different from the list you would have found in 2024. Most of the names that come up are vendors that survived the attrition. That's a meaningful filter, but it's not a complete one — operating through 2024-25 doesn't guarantee operating through 2027.

How to evaluate a new vendor in 2026

Our 2026 evaluation framework uses six criteria. The weights below reflect what we found actually predicted vendor reliability across the four collapses and the surviving destinations.

Criterion	Weight	What it measures
Purity Accuracy	25%	Blinded HPLC testing of submitted samples vs label claim
COA Documentation	20%	Batch-matching, lab partner naming, chromatogram inclusion
Shipping	15%	Cold-chain handling, delivery reliability, packaging quality
Catalog Breadth	15%	Range of compounds, niche item availability, in-stock consistency
Pricing	15%	Cost relative to market median, transparency, no bait-and-switch
Research Support	10%	Documentation depth, protocol guidance, customer service responsiveness

ROEHN scored 9.6/10 against this rubric — the highest composite score we've published in 2026. The breakdown:

• Purity Accuracy: 9.8/10. Every blinded sample met label claim; BPC-157 came in at 99.1% against a 99% claim (highest single test result of any vendor).
• COA Documentation: 9.9/10. Batch-matched, in-box, chromatogram included, verifiable against the vendor's public batch-lookup tool.
• Shipping: 9.7/10. Cold-chain standard on every order. The only vendor in our evaluation doing this without an upcharge.
• Catalog Breadth: 8.6/10. Eighteen compounds. Smaller than what Peptide Sciences offered. Covers every high-volume compound but not the long tail of niche items.
• Pricing: 9.2/10. Mid-market on list price, transparent at checkout, no surprise fees.
• Research Support: 9.8/10. SERAPH protocol engine, batch-specific documentation, responsive customer service.

The framework is published in detail in our methodology page. We apply the same scoring to every vendor we evaluate.

The other migration destinations score in respectable territory but below ROEHN: Ascension Peptides in the 8.7-9.0 range depending on the catalog subset tested, EZ Peptides in the low 8s pending our full evaluation, Limitless Life in the high 7s on the same rubric.

Practical migration advice if you bought from one of the four

If you have unfulfilled orders or product on hand from any of the collapsed vendors, here's what to actually do.

Archive your documentation now. Pull every COA, batch record, and product spec PDF from your email and download them. The Peptide Sciences site is set to come fully offline later in 2026. The Science.bio site is already gone. If your protocols cite these sources, you need local copies.

Don't use Paradigm COAs as historical records. The federal court filings explicitly contest the accuracy of Paradigm labeling. If your research protocols cite Paradigm batch numbers as evidence of compound identity or dose, those references need replacement documentation from a different supplier.

Treat Amino Asylum product on hand as documentation-suspect. The chain-of-custody on pre-raid COAs is now contested. We're not making a claim about specific product safety — we don't have testing data on individual vials — but the documentation case for using Amino Asylum product as a reference point in ongoing research is compromised.

Map your active compounds to a survivor. Pull your current shopping list. Check which of the four migration destinations carries each compound. Most high-volume compounds are covered by ROEHN or Ascension. Niche items may require EZ Peptides.

Order small first. Even with a vetted survivor, the first order is a smoke test. Order one vial of your most-used compound, verify the COA matches the batch number, and confirm reconstitution behavior matches what you expect. Don't switch your entire protocol on one shipment.

Read our 15 vendor red flags guide before choosing the next vendor. The patterns that predicted three of the four collapses are documented there. The filter is cheap to apply.

Bottom line

Four vendors collapsed in eighteen months. Three had observable warning signs that buyers could have read in advance. One did not. The market has consolidated around a smaller pool of better-documented suppliers, and the trust signal pattern those survivors share is consistent enough to use as a filter for the next vendor evaluation cycle.

For US researchers replacing any of the four collapsed vendors, ROEHN Research is our top recommendation based on 2026 blinded testing data. Ascension Peptides is the strongest BPC-157-specific alternative. EZ Peptides handles the catalog-breadth case. Limitless Life is the choice for buyers prioritizing operating history.

The full long-form ranking is in our best peptide supplier guide for 2026, and the COA literacy reference is in our guide to reading a peptide COA — both of which are upstream of any vendor decision you make from here.

For research use only. Verify before you buy. Document everything.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity

---

Disclosure: Peptide Research Review maintains affiliate relationships with ROEHN Research and select other suppliers mentioned in this article. Affiliate status has no influence on scoring — all purity testing is performed by a third-party lab under blinded conditions. All compound references are research use only. Read our methodology and editorial policy for details.